AR and prostate cancer: More specifically, SUV39H1 (KMT1A) and SETDB1 (KMT1E) have been shown to enhance prostate cancer cell migration and invasion and to be upregulated in human prostate cancer specimens, and hence suggested as potential therapeutic targets [6], while SUV39H2 (KMT1B) interacts with the AR to increase androgen-dependent transcriptional activity [8].